Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 12/20 | 0.71 |
| ▸ | MAOA | P21397 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17820957 | 0.89 | TTR (0.71) | TTRMAOAKDM4EMEN1ALDH1A1 | |
| SCHEMBL2628182 | 0.84 | TTR (0.52) | TTRMAOAKDM4EALDH1A1 | |
| SCHEMBL4514082 | 0.83 | TTR (0.71) | TTRMAOAKDM4EMEN1ALDH1A1 | |
| SCHEMBL4512899 | 0.83 | TTR (1.00) | TTRMAOAKDM4EMEN1ALDH1A1 | |
| SCHEMBL490132 | 0.81 | TTR (0.52) | TTRMAOAKDM4EALDH1A1HPGD | |
| SCHEMBL29547886 | 0.81 | MAOA (0.51) | TTRMAOAKDM4EALDH1A1HPGD | |
| SCHEMBL19642433 | 0.81 | MAOA (0.51) | TTRMAOAKDM4EALDH1A1HPGD | |
| SCHEMBL27719238 | 0.80 | AKR1B1 (0.49) | TTRMAOAKDM4EALDH1A1HPGD | |
| SCHEMBL4517758 | 0.80 | MAOA (0.70) | TTRMAOAKDM4EMEN1ALDH1A1 | |
| SCHEMBL10623602 | 0.80 | TTR (0.83) | TTRMAOAKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8350041-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-08 | — | — | US | disclosed |
| US-8350041-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-08 | — | — | US | disclosed |
| US-8350041-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-08 | — | — | US | disclosed |
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R (US) | 2012-04-19 | — | — | US | disclosed |
| US-8106207-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-01-31 | — | — | US | disclosed |
| US-8106207-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-01-31 | — | — | US | disclosed |
| US-8106207-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-01-31 | — | — | US | disclosed |
| US-20110245291-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R | 2011-10-06 | — | — | US | disclosed |
| US-7589103-B2 | Especially 2-aminocarbonyl-9-(thio)xanthenylidene-8-aza-bicyclo[3.2.1] octane derivatives are used in pharmaceutical and veterinary compositions for treating mild to severe pain and various diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-15 | — | — | US | disclosed |
| CN-100513407-C | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-15 | — | — | CN | disclosed |
| CN-101119992-A | Tricyclic delta opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-06 | — | — | CN | disclosed |
| EP-1833825-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-19 | — | — | EP | disclosed |
| CN-1839135-A | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2006-09-27 | — | — | CN | disclosed |
| WO-2006069277-A1 | TRICYCLIC δ-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135524-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-22 | — | — | US | disclosed |
| EP-1644373-A1 | TRICYCLIC DELTA OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005003131-A1 | TRICYCLIC DELTA OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-13 | — | — | WO | disclosed |
| US-20050009860-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135524-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | TTR 2536/4885MAOA 948/4885KDM4E 2174/4885 |
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | TTR 2536/4885MAOA 948/4885KDM4E 2174/4885 |
| US-20050009860-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | TTR 2536/4885MAOA 948/4885KDM4E 2174/4885 |
| US-20110245291-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | TTR 2536/4885MAOA 948/4885KDM4E 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.